The POWER KNEE achieves important reimbursement milestone

    




 QUEBEC, Aug. 21, 2012 /CNW Telbec/ - Ossur, a global leader in  non-invasive orthopedics, announced in its second-quarter report that  the POWER KNEE was accepted into the reimbursement system in the U.S.,  effective as of January 2013. The allocation of the reimbursement code  by the Centers for Medicare & Medicaid Services ("CMS") for the POWER  KNEE is a very important milestone and confirms the acceptance of  bionic products as the next generation of prosthetics. The  reimbursement price has not yet been determined. The allocation of the  code is not expected to have any material impact on sales of the POWER  KNEE in 2012. 

 "This is a major commercial achievement for Ossur as CMS reimbursement  is a critical step toward adoption of the Power Knee. Victhom is very  proud that its collaboration with Ossur has generated such an  exceptional product that will significantly improve the quality of life  for above-knee amputees," stated Mr. Normand Rivard, President & CEO of  Victhom. 

 Ossur is the world leader in bringing the most innovative prosthetic  solutions to market. Developed in partnership with Victhom Human  Bionics Inc., the POWER KNEE is the world's first and only  motor-powered, artificially intelligent prosthesis for above-knee  amputees that restores lost muscle function and enables amputees to  perform normal daily functions without even thinking about their next  movement. This breakthrough provides unprecedented stability, safety  and confidence for any above-knee amputee. 

 About Victhom 

 Victhom is a company which owns patents in the field of orthotics and  prosthetics ("O&P"), including intellectual property used in the Power  Knee, the world's first and only motor-powered prosthesis for  above-knee amputees, a product distributed under license agreement by  Ossur, a global leader in the O&P market. The Company also has a  royalty agreement related to the Neurostep(®) System and neuromodulation products in other indications (sleep apnea  and epilepsy) using the Neurobionix technology platform currently under  development by Neurostream Technologies, a General Partnership now  owned by Otto Bock, a global leader in the O&P market. 

 FORWARD-LOOKING STATEMENTS 

 Some of the statements made herein may constitute forward-looking  statements. These statements relate to future events or our future  financial performance and involve known and unknown risks,  uncertainties and other factors that may cause Victhom's actual  results, performance or achievements to be materially different from  those expressed or implied by any of Victhom's statements. Actual  events or results may differ materially. We disclaim any intention, and  assume no obligation, to update these forward-looking statements. 

  



VICTHOM HUMAN BIONICS INC.


CONTACT:  Source: Victhom Human Bionics Inc.For more information: Normand RivardPresident & CEOVicthom Human Bionics Inc.  Tel.: [phone]  Fax: (438) [e-mail] 


    

Copyright